{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-025569","form_type":"8-K","ticker":"ETON","cik":"0001710340","company_name":"Eton Pharmaceuticals, Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.207633+00:00","generated_at":"2026-05-31T11:03:40.956740+00:00","sec_items":["2.02"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Eton Q2 product sales up 40% YoY to $9.1M; ET-400 NDA accepted with Feb 2025 PDUFA","bullets":["Product sales and royalty revenue $9.1M, up 40% YoY and 14% sequentially; 14th straight quarter of sequential growth.","Net loss of $2.9M ($0.11/share) including $2.0M ET-400 filing fee; prior year net income $4.6M included $5.5M royalty sale.","ALKINDI SPRINKLE revenue grew 63% YoY; Carglumic Acid sales continue to exceed expectations.","NDA for ET-400 (hydrocortisone oral solution) accepted with PDUFA date Feb 28, 2025; launch quantities planned Q4 2024.","Cash $17.7M; generated $1.3M operating cash flow in Q2; expects positive cash flow for remainder of 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-025569","json":"https://secwatch.observer/filing/0001437749-24-025569.json","markdown":"https://secwatch.observer/filing/0001437749-24-025569.md","text":"https://secwatch.observer/filing/0001437749-24-025569.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1710340/000143774924025569/0001437749-24-025569-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1710340/000143774924025569/eton20240802_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:03:40.956740+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}